Lipocomb

Ezetimibe and Rosuvastatin, the active ingredients in Lipocomb, are a combination lipid‑lowering agent presented as an oral tablet for oral use. It treats elevated cholesterol and triglyceride levels in adults with primary hypercholesterolemia, mixed dyslipidemia, or familial hypercholesterolemia.

GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulated manufacturing and quality‑assured distribution.

Lipocomb, a combination lipid‑lowering therapy, is used to manage disorders of cholesterol metabolism.

- Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels in patients with primary high cholesterol. - Mixed dyslipidemia: lowers LDL‑cholesterol, triglycerides and modestly raises HDL‑cholesterol in patients with combined lipid abnormalities. - Familial hypercholesterolemia: helps achieve target lipid levels in individuals with genetically elevated cholesterol.

Lipocomb may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramping in the stomach area. - Diarrhea: loose, watery stools. - Myalgia: muscle aches or soreness. - Elevated liver enzymes: increase in ALT or AST levels. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Acute liver injury: marked elevation of liver enzymes with jaundice. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and vomiting.

Before prescribing Lipocomb, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness or weakness. - Renal function evaluation: check creatinine clearance in patients with kidney disease. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors or cytochrome‑mediated agents. - Contraindication in active liver disease: do not use in patients with unexplained persistent elevations of hepatic enzymes. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Lipocomb can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: increases rosuvastatin exposure, raising risk of myopathy. - Gemfibrozil: markedly raises rosuvastatin levels, heightening rhabdomyolysis risk. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): elevate rosuvastatin concentrations. - Cholesterol‑binding resins (e.g., cholestyramine, colestipol): decrease ezetimibe absorption.

Moderate Interactions (Monitor Closely): - Warfarin: statins may potentiate anticoagulant effect, monitor INR. - Amiodarone: may increase rosuvastatin plasma levels. - Niacin: combined use can raise risk of muscle toxicity. - Fibrates (e.g., fenofibrate): monitor for muscle‑related side effects. - Digoxin: rosuvastatin may affect digoxin levels; check serum concentrations.